Rhythm Pharmaceuticals (RYTM) Upgraded by BidaskClub to “Strong-Buy”

Share on StockTwits

BidaskClub upgraded shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) from a buy rating to a strong-buy rating in a report released on Thursday morning.

A number of other equities analysts also recently weighed in on the company. Needham & Company LLC set a $42.00 target price on Rhythm Pharmaceuticals and gave the company a buy rating in a report on Friday, December 14th. Stifel Nicolaus reiterated a hold rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 13th. Zacks Investment Research downgraded Rhythm Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, November 15th. Finally, ValuEngine upgraded Rhythm Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $38.25.

RYTM stock traded down $0.29 during mid-day trading on Thursday, reaching $29.01. 81,400 shares of the stock traded hands, compared to its average volume of 123,013. Rhythm Pharmaceuticals has a 52-week low of $16.80 and a 52-week high of $37.23. The firm has a market capitalization of $998.94 million, a PE ratio of -10.25 and a beta of 1.85.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Friday, November 9th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). As a group, analysts forecast that Rhythm Pharmaceuticals will post -2.2 EPS for the current year.

In other Rhythm Pharmaceuticals news, insider Der Ploeg Leonardus H.T. Van sold 38,000 shares of the stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $30.09, for a total transaction of $1,143,420.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Keith Michael Gottesdiener sold 16,500 shares of the stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $30.08, for a total value of $496,320.00. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its position in shares of Rhythm Pharmaceuticals by 46.6% in the third quarter. Legal & General Group Plc now owns 2,675 shares of the company’s stock valued at $78,000 after acquiring an additional 850 shares during the period. Vanguard Group Inc boosted its position in shares of Rhythm Pharmaceuticals by 12.3% in the third quarter. Vanguard Group Inc now owns 1,048,186 shares of the company’s stock valued at $30,575,000 after acquiring an additional 115,177 shares during the period. Federated Investors Inc. PA boosted its position in shares of Rhythm Pharmaceuticals by 216.2% in the third quarter. Federated Investors Inc. PA now owns 790,421 shares of the company’s stock valued at $23,057,000 after acquiring an additional 540,421 shares during the period. Vanguard Group Inc. boosted its position in shares of Rhythm Pharmaceuticals by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,048,186 shares of the company’s stock valued at $30,575,000 after acquiring an additional 115,177 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of Rhythm Pharmaceuticals by 36.1% in the third quarter. Teachers Advisors LLC now owns 27,766 shares of the company’s stock valued at $810,000 after acquiring an additional 7,360 shares during the period. Institutional investors own 90.42% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

See Also: What Factors Can Affect Return on Equity?

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Alliance MMA  and Vail Resorts  Financial Comparison
Alliance MMA and Vail Resorts Financial Comparison
WSFS Financial Co.  Given Average Rating of “Hold” by Brokerages
WSFS Financial Co. Given Average Rating of “Hold” by Brokerages
Zuora Inc  Given Average Recommendation of “Buy” by Brokerages
Zuora Inc Given Average Recommendation of “Buy” by Brokerages
Maxar Technologies  Upgraded to Hold by ValuEngine
Maxar Technologies Upgraded to Hold by ValuEngine
Fly Leasing  Downgraded by ValuEngine to Strong Sell
Fly Leasing Downgraded by ValuEngine to Strong Sell
Alpha and Omega Semiconductor  Upgraded at ValuEngine
Alpha and Omega Semiconductor Upgraded at ValuEngine


Leave a Reply

 
© 2006-2019 Zolmax.